Protein PRMT6 Curbs Gut Inflammation in Mice
Researchers report that PRMT6 suppresses the inflammatory cytokine IL-1β in mouse models of colitis, with reduced levels linked to inflammatory bowel disease.
Updated on Nov. 4, 2026 in Life Sciences
Researchers report that Protein Arginine Methyltransferase 6 (PRMT6) suppresses intestinal inflammation by epigenetically repressing IL-1β in mouse models of colitis. The protein is consistently downregulated in inflammatory bowel disease samples compared with healthy controls.
Why it matters
Inflammatory bowel disease involves persistent intestinal inflammation, and identifying a regulator that restrains IL-1β offers a mechanistic target for future study. The findings connect an epigenetic enzyme to a specific inflammatory mediator in the gut.
The mechanism was tested in DSS- and TNBS-induced colitis mouse models, where Prmt6-deficient animals showed greater susceptibility and systemic IL-1β elevation than controls. Whether these mouse findings translate to human inflammatory bowel disease remains unresolved in the reported data.
The details
PRMT6 suppresses Il1b transcription by interacting with RBBP5, disrupting SET1A complex assembly and reducing H3K4me3 enrichment at the Il1b promoter independently of its canonical H3R2me2a activity. The NF-κB subunit p50 transcriptionally silences PRMT6 during inflammation, and pharmacological inhibition of p50 restored PRMT6 expression and protected mice from DSS-induced colitis in a PRMT6-dependent manner.
Health Landscape
The finding places an epigenetic regulator, PRMT6, within the NF-κB-driven inflammatory circuit that is central to inflammatory bowel disease research. It suggests that p50 inhibition could restore protective chromatin control over IL-1β in the gut.
Mouse-model findings like these typically require years of further research before any therapeutic application could reach patients with inflammatory bowel disease. For now, the work identifies a candidate pathway that researchers may test in future studies.
The takeaway
The study identifies PRMT6 as a brake on IL-1β in the gut, and its silencing by p50 suggests a possible target for future inflammatory bowel disease research. Readers should note that these results come from mouse models and have not been confirmed in human patients.
Further reading
Explore more in Life Sciences for context on how gene regulation shapes inflammatory disease.
Source note: This article includes information reported by Nature.
